BIOSTAR PHARM-B: May 2026 Filing Shows Stable Capital Base and Sufficient Public Float

Bulletin Express
06/02

Beijing Biostar Pharmaceuticals Co., Ltd. (BIOSTAR PHARM-B) reported no changes in its share capital structure for the month ended 31 May 2026, according to its Monthly Return filed with Hong Kong Exchanges and Clearing Limited on 02 June 2026.

Registered and Issued Share Capital • Registered share capital remained at RMB 364.59 million, divided into 364.59 million H-shares with a par value of RMB 1 each. • The issued share count was unchanged at 364.59 million shares, and the company held no treasury shares at month-end.

Public Float Compliance The company confirmed compliance with the Main Board’s minimum public float requirement of 25% of issued H-shares as of 31 May 2026.

Corporate Actions • No share issuances, cancellations, repurchases, option grants, warrant exercises, convertible securities, or other equity-related transactions were recorded during the month.

Recent Context Biostar completed full share circulation on 30 March 2026 by converting 147.87 million unlisted shares into H-shares, a move that established the current share count and capital structure.

Administrative Details The filing was submitted by Company Secretary Chan Yik Pun, with no additional confirmations or amendments required under the Listing Rules.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10